Physician profile
Patrick G Tempera
NPI 1508830050
$2,486.38
in general payments reported to CMS, 2019-2025
29 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $149 · 2021: $342 · 2022: $487 · 2023: $225 · 2024: $370 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.18 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.82 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $309.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.11 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $195.36 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $173.72 | 2019-2025 | Tremfya |
| Braintree Laboratories, INC. | $134.63 | 2019-2023 | Sutab |
| Boston Scientific Corporation | $109.61 | 2025 | Exalt Model D |
| Gilead Sciences, INC. | $103.42 | 2019-2024 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $100.22 | 2019-2022 | |
| Lilly USA, LLC | $86.08 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $65.52 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $56.34 | 2019-2023 | Ocaliva |
| Medtronic, INC. | $45.40 | 2022 | |
| Nestle Healthcare Nutrition INC. | $36.00 | 2021 | |
| Genzyme Corporation | $35.83 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $33.29 | 2019 | |
| Merck Sharp & Dohme LLC | $28.50 | 2019-2021 | |
| Daiichi Sankyo INC. | $25.95 | 2022 | |
| Aimmune Therapeutics, INC. | $16.78 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $16.63 | 2025 | Rezdiffra |
| Celltrion USA INC. | $14.69 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $14.54 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.34 | 2024 | |
| Vivus LLC | $14.29 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.50 | 2022 | |
| Alfasigma USA, INC. | $13.39 | 2020 | |
| Qol Medical, LLC | $11.66 | 2022 | |
| Ferring Pharmaceuticals INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tempera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.